Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Apogee Therapeutics (Nasdaq: APGE) has announced a conference call and webcast scheduled for July 7, 2025, at 8:00 a.m. ET to discuss Part A 16-week data from their Phase 2 APEX trial of APG777 in patients with moderate-to-severe atopic dermatitis.
The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology conditions, will present results for APG777, their candidate targeting atopic dermatitis, asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The webcast will be accessible through the company's website, with a replay available after the presentation.
Apogee Therapeutics (Nasdaq: APGE) ha annunciato una conference call e un webcast programmati per il 7 luglio 2025 alle 8:00 ET per discutere i dati della Parte A di 16 settimane del loro studio di Fase 2 APEX su APG777 in pazienti con dermatite atopica da moderata a grave.
La societ脿 biotecnologica in fase clinica, specializzata nello sviluppo di nuovi biologici per condizioni infiammatorie e immunologiche, presenter脿 i risultati di APG777, il loro candidato terapeutico rivolto alla dermatite atopica, asma, esofagite eosinofila (EoE) e broncopneumopatia cronica ostruttiva (BPCO). Il webcast sar脿 disponibile sul sito web dell'azienda, con la possibilit脿 di rivederlo dopo la presentazione.
Apogee Therapeutics (Nasdaq: APGE) ha anunciado una llamada de conferencia y un webcast programados para el 7 de julio de 2025 a las 8:00 a.m. ET para discutir los datos de la Parte A de 16 semanas de su ensayo de Fase 2 APEX con APG777 en pacientes con dermatitis at贸pica de moderada a grave.
La empresa biotecnol贸gica en etapa cl铆nica, enfocada en desarrollar nuevos biol贸gicos para enfermedades inflamatorias e inmunol贸gicas, presentar谩 los resultados de APG777, su candidato dirigido a la dermatitis at贸pica, asma, esofagitis eosinof铆lica (EoE) y enfermedad pulmonar obstructiva cr贸nica (EPOC). El webcast estar谩 accesible a trav茅s del sitio web de la compa帽铆a, con una repetici贸n disponible despu茅s de la presentaci贸n.
Apogee Therapeutics (雮橃姢雼�: APGE)电� 2025雲� 7鞗� 7鞚� 鞓れ爠 8鞁� ET鞐� 16欤检皑 Part A 雿办澊韯办棎 雽�頃� 雲检潣頃樀鐢 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 鞓堨爼頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚吹鐢 欷戨摫霃勳棎靹� 欷戩 鞎勴啝頂� 頂茧秬鞐� 頇橃瀽毳� 雽�靸侅溂搿� 頃� Phase 2 APEX 鞁滍棙鞚� APG777 甏�霠� 雮挫毄鞛呺媹雼�.
鞐检 氚� 氅挫棴 歆堩櫂鞚� 鞙勴暅 順侅嫚鞝侅澑 氚旍澊鞓れ潣鞎巾拡 臧滊皽鞐� 欤茧牓頃樀鐢 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 須岇偓鞚� Apogee Therapeutics电� 鞎勴啝頂� 頂茧秬鞐�, 觳滌嫕, 順胳偘甑劚 鞁濍弰鞐�(EoE), 毵岇劚 韽愳噭靹� 韽愳頇�(COPD)鞚� 雽�靸侅溂搿� 頃樀鐢 頉勲炒氍检 APG777鞚� 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼电� 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 鞁滌箔 臧�電ロ晿氅�, 氚滍憸 頉� 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�.
Apogee Therapeutics (Nasdaq : APGE) a annonc茅 une conf茅rence t茅l茅phonique et un webcast pr茅vus pour le 7 juillet 2025 脿 8h00 ET afin de discuter des donn茅es de 16 semaines de la Partie A de leur essai de Phase 2 APEX sur APG777 chez des patients atteints de dermatite atopique mod茅r茅e 脿 s茅v猫re.
Cette soci茅t茅 biotechnologique en phase clinique, sp茅cialis茅e dans le d茅veloppement de nouveaux biologiques pour les maladies inflammatoires et immunologiques, pr茅sentera les r茅sultats d鈥橝PG777, leur candidat ciblant la dermatite atopique, l鈥檃sthme, l鈥櫯搒ophagite 脿 茅osinophiles (EoE) et la maladie pulmonaire obstructive chronique (MPOC). Le webcast sera accessible via le site web de la soci茅t茅, avec une rediffusion disponible apr猫s la pr茅sentation.
Apogee Therapeutics (Nasdaq: APGE) hat eine Telefonkonferenz und ein Webcast f眉r den 7. Juli 2025 um 8:00 Uhr ET angek眉ndigt, um die 16-w枚chigen Daten von Teil A ihrer Phase-2-APEX-Studie mit APG777 bei Patienten mit mittelschwerer bis schwerer atopischer Dermatitis zu besprechen.
Das biotechnologische Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Biologika f眉r entz眉ndliche und immunologische Erkrankungen spezialisiert hat, wird Ergebnisse zu APG777 pr盲sentieren, ihrem Wirkstoffkandidaten f眉r atopische Dermatitis, Asthma, eosinophile 脰sophagitis (EoE) und chronisch obstruktive Lungenerkrankung (COPD). Das Webcast ist 眉ber die Webseite des Unternehmens zug盲nglich, eine Wiederholung wird nach der Pr盲sentation verf眉gbar sein.
- None.
- None.
Webcast to be held Monday, July 7th at 8:00 a.m. ET
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Webcast Details
Apogee Therapeutics鈥� live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th聽at 8:00 a.m. ET. The live webcast can be accessed via this聽聽or the Investors section on the Company鈥檚 website at聽. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee鈥檚 antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company鈥檚 most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today鈥檚 standard of care. For more information, please visit .
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Media Contact:
Dan Budwick
1AB
FAQ
When will Apogee Therapeutics (APGE) report Phase 2 APEX trial data for APG777?
How can investors access Apogee Therapeutics' Phase 2 APEX trial results webcast?
What conditions is Apogee Therapeutics' APG777 being developed to treat?
What type of data will be presented in Apogee's Phase 2 APEX trial results?
